You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

The Evolving Treatment Landscape for Moderate to Severe Psoriasis: What to Use, How to Choose

  • Authors: Melinda Gooderham, MD
  • CPD Released: 1/19/2022
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 1/19/2023
Start Activity


Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US healthcare professionals, specifically dermatologists, rheumatologists, and primary care physicians.

The goal of this activity is to educate on the factors influencing treatment decisions and selection of therapy in patients with moderate to severe psoriasis in an evolving treatment landscape.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Factors influencing treatment selection in a complex treatment landscape
    • Selection of an appropriate biologic agent for a patient with psoriasis
  • Demonstrate greater confidence in their ability to
    • Effectively manage patients with psoriasis, using inhibitors of the IL-23/IL-17 pathway


Disclosures

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.


Faculty

  • Melinda Gooderham, MD

    Medical Director at SKiN Centre for Dermatology
    Investigator with Probity Medical Research
    Assistant Professor at Queens University
    Consultant Physician at the Peterborough Regional Health Centre
    Peterborough, Ontario, Canada

    Disclosures

    Disclosure: Melinda Gooderham, MD, has the following relevant financial relationships:
    Advisor or consultant for: AbbVie; Akros; Amgen; Arcutis; Bausch; Boehringer Ingelheim; Bristol Myers Squibb Company; Dermavent; Galderma; Janssen; Kyowa Kirin; Leo; Lilly; Novartis; Pfizer; Sanofi; Sun; UCB
    Speaker or a member of a speakers bureau for: AbbVie; Amgen; Arcutis; Bausch; Boehringer Ingelheim; Bristol Myers Squibb Company; Galderma; Janssen; Leo; Lilly; Novartis; Pfizer; Regeneron; Sanofi; Sun; UCB
    Grants for clinical research from: AbbVie; Akros; Amgen; Arcutis; Bausch; Boehringer Ingelheim; Bristol Myers Squibb Company; Coherus; Dermavent; Dermira; Galderma; GlaxoSmithKline; Janssen; Kyowa Kirin; Leo; Lilly; Novartis; Pfizer; Sanofi; Sienna; Sun; UCB

Editors

  • Marinella Calle, PhD, CMPP

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Disclosure: Marinella Calle, PhD, CMPP, has disclosed no relevant financial relationships.

  • Megan Breuer, PhD, CMPP

    Medical Writer, WebMD Global, LLC

    Disclosures

    Disclosure: Megan Breuer, PhD, CMPP, has disclosed no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

    Associate Director, Accreditation and Compliance

    Disclosures

    Disclosure: Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 1.0 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

The Evolving Treatment Landscape for Moderate to Severe Psoriasis: What to Use, How to Choose

Authors: Melinda Gooderham, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CPD Released: 1/19/2022

Valid for credit through: 1/19/2023

processing....

The following cases are modeled on the interactive grand rounds approach. The questions within the activity are designed to test your current knowledge. After each question, you will be able to see whether you answered correctly and read evidence-based information that supports the most appropriate answer choice. The questions are designed to challenge you; you will not be penalized for answering the questions incorrectly. At the end of the activity, there will be a short post-test assessment based on the material presented.

CASE 1: INTRODUCTION

Emily is an elementary school teacher, aged 42 years, with confirmed moderate to severe psoriasis on her legs, torso, and scalp. When she was first diagnosed, her affected body surface area (BSA) was 15%. She has several plaques located at the hair border on her face and neck and are highly visible. Her quality of life is severely impacted, and she regularly stays home from work due to symptoms and fatigue. Emily mentions she is starting to feel depressed and anxious because of her psoriasis. She is embarrassed to see family and friends because of her skin condition and is irritated by the almost constant itching, especially on her scalp. Emily is currently receiving treatment with adalimumab but has not yet achieved symptom control. Her affected BSA did decrease to 4%, but she never achieved complete skin clearance, and her scalp is still itchy.

She is frustrated and does not know what to do next.

  • Print